Clinical consequences of polycystic ovary syndrome in menopause

Beata Banaszewska; Leszek Pawelczyk; Monika Serdyńska; Robert Spaczyński

eISSN: 2299-0038
ISSN: 1643-8876

Menopause Review/Przegląd Menopauzalny

Current issue Archive Manuscripts accepted About the journal Special Issues Editorial board Abstracting and indexing Subscription Contact Instructions for authors Publication charge Ethical standards and procedures

Editorial System

Submit your Manuscript

Editorial Policies

Sarajevo Declaration on Integrity and Visibility of Scholarly Publications

Open access

2/2002
vol. 1

Send email

Copy url:

abstract:

Clinical consequences of polycystic ovary syndrome in menopause

Beata Banaszewska

,

Leszek Pawelczyk

,

Monika Serdyńska

,

Robert Spaczyński

(Prz Menopauz 2002, 2: 7–13)

Online publish date: 2004/03/03

View full text Get citation

Polycystic ovary syndrome (PCOS) is the most common endocrine abnormality of premenopausal women. It has been established that hyperinsulinaemia is a fundamental disturbance in many women with polycystic ovary syndrome and has significant metabolic effect that could have an impact after the menopause. Women with a history of PCOS have higher levels of several cardiovascular risk factors including hyperlipidemia, diabetes, hypertension. Additionally, endometrial cancer, due to unopposed estrogen action is more common in patients with polycystic ovary syndrome. Early prevention and treatment of PCOS patients may avoid many serious postmenopausal consequnces.

Clinical consequences of polycystic ovary syndrome in menopause

Beata Banaszewska , Leszek Pawelczyk , Monika Serdyńska , Robert Spaczyński

Beata Banaszewska

,

Leszek Pawelczyk

,

Monika Serdyńska

,

Robert Spaczyński